MX2022007219A - Compuestos y su uso para el tratamiento contra la deficiencia de ¿1- antitripsina. - Google Patents

Compuestos y su uso para el tratamiento contra la deficiencia de ¿1- antitripsina.

Info

Publication number
MX2022007219A
MX2022007219A MX2022007219A MX2022007219A MX2022007219A MX 2022007219 A MX2022007219 A MX 2022007219A MX 2022007219 A MX2022007219 A MX 2022007219A MX 2022007219 A MX2022007219 A MX 2022007219A MX 2022007219 A MX2022007219 A MX 2022007219A
Authority
MX
Mexico
Prior art keywords
compounds
treatment
antitrypsin deficiency
antitrypsin
deficiency
Prior art date
Application number
MX2022007219A
Other languages
English (en)
Inventor
James Andrew Huntington
Nigel Ramsden
David John Fox
James Michael Tomlinson
Original Assignee
Z Factor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Z Factor Ltd filed Critical Z Factor Ltd
Publication of MX2022007219A publication Critical patent/MX2022007219A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Compuestos y su uso para el tratamiento contra la deficiencia de ¿1-antitripsina. La invención se refiere a compuestos especificados de benzamida de la fórmula (1) y a composiciones farmacéuticas que contienen los compuestos. Los compuestos pueden ser inductores de ¿1-antitripsina (A1AT) y se pueden utilizar en el tratamiento contra una enfermedad o trastorno tal como la deficiencia de ¿1-antitripsina (A1AD o AATD).
MX2022007219A 2019-12-13 2020-12-11 Compuestos y su uso para el tratamiento contra la deficiencia de ¿1- antitripsina. MX2022007219A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1918414.2A GB201918414D0 (en) 2019-12-13 2019-12-13 Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
PCT/GB2020/053194 WO2021116709A1 (en) 2019-12-13 2020-12-11 COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY

Publications (1)

Publication Number Publication Date
MX2022007219A true MX2022007219A (es) 2022-09-07

Family

ID=69186832

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007219A MX2022007219A (es) 2019-12-13 2020-12-11 Compuestos y su uso para el tratamiento contra la deficiencia de ¿1- antitripsina.

Country Status (12)

Country Link
US (1) US20230096524A1 (es)
EP (1) EP4072675B1 (es)
JP (1) JP2023505587A (es)
KR (1) KR20220127823A (es)
CN (1) CN115003381A (es)
AU (1) AU2020401779A1 (es)
BR (1) BR112022011566A2 (es)
CA (1) CA3164303A1 (es)
GB (1) GB201918414D0 (es)
IL (1) IL293832A (es)
MX (1) MX2022007219A (es)
WO (1) WO2021116709A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820450D0 (en) * 2018-12-14 2019-01-30 Z Factor Ltd Compound and its use for the treatment of alpha1-antitryspin deficiency
WO2022263829A1 (en) * 2021-06-16 2022-12-22 Z Factor Limited COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2114141A2 (en) * 2007-01-10 2009-11-11 University of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
CN113286586A (zh) 2018-06-22 2021-08-20 Ucl商业有限公司 新化合物
WO2020081257A1 (en) 2018-10-05 2020-04-23 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
UY38696A (es) 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina

Also Published As

Publication number Publication date
US20230096524A1 (en) 2023-03-30
EP4072675A1 (en) 2022-10-19
CN115003381A (zh) 2022-09-02
BR112022011566A2 (pt) 2022-08-30
WO2021116709A1 (en) 2021-06-17
EP4072675B1 (en) 2024-04-24
AU2020401779A1 (en) 2022-07-21
IL293832A (en) 2022-08-01
CA3164303A1 (en) 2021-06-17
KR20220127823A (ko) 2022-09-20
GB201918414D0 (en) 2020-01-29
JP2023505587A (ja) 2023-02-09

Similar Documents

Publication Publication Date Title
MX2022015812A (es) Inhibidores de cisteina proteasas y sus metodos de uso.
MX2021004431A (es) Procesos novedosos.
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
MX2009014235A (es) 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
MX2023009856A (es) Dosificacion optimizada de diaminofenotiazinas en poblaciones.
MX2022007219A (es) Compuestos y su uso para el tratamiento contra la deficiencia de ¿1- antitripsina.
MX2021006884A (es) Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina.
MX2022007175A (es) Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina.
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
MX2023001997A (es) Compuestos biciclicos, composiciones y usos de los mismos.
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
CR20210460A (es) Compuestos útiles en la terapia del vih
MX2022007174A (es) Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina.
MX2022007176A (es) 4-((2-oxopyri din-1 (2h)-yl)metil)benzamidas para el tratamiento de la deficiencia de alfa1-antitripsina.
EA202192925A1 (ru) Твердые формы ингибитора glyt1
BRPI0516001A (pt) formas cristalinas de 3-[5-cloro-4-[(2, 4-difluorobenzil) óxi]-6-oxopirimidin-1(6h)-il]-n-(2-hidroxietil)-4-metilben zamida
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
IT201900021564A1 (it) Composizione nutraceutica o farmaceutica comprendente ferro pirofosfato per l’uso nel trattamento e/o nella prevenzione di condizioni o patologie caratterizzate da carenza di ferro
MX2020010552A (es) Derivados de bumetanida para el tratamiento de la hiperhidrosis.
MX2021015333A (es) Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4.
PH12017501668A1 (en) Bace1 inhibitors
GB0407025D0 (en) Novel compounds
MX2022007220A (es) Compuestos y su uso para el tratamiento contra la deficiencia de ¿1- antitripsina.